Cargando…

Feasibility of sustained response through long-term dosing in food allergy immunotherapy

BACKGROUND: Clinical trials using oral immunotherapy (OIT) for the treatment of food allergies have shown promising results. We previously demonstrated the feasibility of desensitization for up to 5 food allergens simultaneously through OIT. In this observational study, we report the findings of lon...

Descripción completa

Detalles Bibliográficos
Autores principales: Andorf, Sandra, Manohar, Monali, Dominguez, Tina, Block, Whitney, Tupa, Dana, Kshirsagar, Rohun A., Sampath, Vanitha, Chinthrajah, R. Sharon, Nadeau, Kari C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738818/
https://www.ncbi.nlm.nih.gov/pubmed/29296108
http://dx.doi.org/10.1186/s13223-017-0224-7
Descripción
Sumario:BACKGROUND: Clinical trials using oral immunotherapy (OIT) for the treatment of food allergies have shown promising results. We previously demonstrated the feasibility of desensitization for up to 5 food allergens simultaneously through OIT. In this observational study, we report the findings of long-term follow-up (LTFU) of the participants treated through a single site OIT phase 1 trial. METHODS: The participants (n = 46) were followed up to 72 months since the time they reached 2 g maintenance dose per food in the initial phase 1 trial. During the long-term maintenance dosing, participants continued or reduced the initial maintenance dose of food allergen protein to high (median 2 g protein) vs. low (median 300 mg protein). Participant follow-up included clinical monitoring, standardized OFCs, and in some cases, skin prick tests and measurement of allergen-specific IgE and IgG(4). RESULTS: Irrespective of the high vs. low long-term maintenance dose during LTFU, all participants were able to ingest 2 g protein of each food allergen protein during OFCs performed at the end of our LTFU. CONCLUSION: Our LTFU cohort of food OIT participants from a single site, phase 1 OIT study, supports the feasibility of sustained desensitization through long-term maintenance dosing. Trial registration Registry: Clinicaltrial.gov. Registration numbers: NCT01490177 (original study); NCT03234764 (LTFU study). Date of registration: November 29, 2011 (original study); July 26, 2017 (LTFU study, registered) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13223-017-0224-7) contains supplementary material, which is available to authorized users.